Evidence map›Paper›PMID 31705219›Full record

ReviewInternational journal of clinical oncology2020

Corticosteroid switch after progression on abiraterone acetate plus prednisone.

Giandomenico Roviello, Navid Sobhani, Silvia Paola Corona, Alberto D'Angelo

Open access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in International journal of clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Giandomenico RovielloDepartment of Health Sciences, University of Florence, Viale Pieraccini, 6, 50139, Florence, Italy. giandomenicoroviello@hotmail.it.
Navid SobhaniDepartment of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Hospital, Strada Di Fiume 447, 34149, Trieste, Italy.
Silvia Paola CoronaDepartment of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Hospital, Strada Di Fiume 447, 34149, Trieste, Italy.
Alberto D'AngeloDepartment of Biology and Biochemistry, University of Bath, Bath, B2 7AY, UK.
Azienda Socio Sanitaria Territoriale di CremonaUniversity of Bath · GBUniversity of Florence · ITUniversity of Trieste · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAbiraterone acetate plus prednisone is approved in metastatic castration-resistant prostate cancer. There is some evidence in favour of the steroid switch from prednisone to dexamethasone in patients who progressed whilst on abiraterone acetate plus prednisone or prednisolone. MATERIALS AND

methodsThe aim of this review is to discuss the results from the clinical studies available, examining potential mechanisms of action and patient selection criteria for this treatment option.

resultsA total of four studies were evaluated. Among possible eligibility criteria for steroid switch, we found: PSA progression without any radiological or clinical progression during abiraterone acetate + prednisone; no high-grade adverse events related to CYP-17 inhibition; and unfitness for chemotherapy or radium-223.

conclusionAlthough large randomized prospective trials are warranted, steroid switch seems to offer a good option for certain patients treated with abiraterone acetate plus prednisone or prednisolone.

Indexed as

Abiraterone AcetateAdrenal Cortex HormonesAgedAndrostenesAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneHumansMaleMiddle AgedPatient SelectionPrednisolonePrednisoneProstatic Neoplasms, Castration-ResistantTreatment OutcomeabirateroneAbiraterone AcetateAdrenal Cortex HormonesAndrostenesDexamethasonePrednisolonePrednisoneAbirateroneDexamethasonePrednisoneSwitch

Identifiers

PMID31705219
OpenAlexW2986294136

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.